Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

July 31, 2000

Primary Completion Date

August 31, 2002

Study Completion Date

August 31, 2002

Conditions
Breast Cancer
Interventions
DRUG

arzoxifene hydrochloride

DRUG

tamoxifen citrate

Trial Locations (9)

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

60153

Loyola University Medical Center, Maywood

75246

U.S. Oncology Research Inc., Dallas

92262

Comprehensive Cancer Centers of the Desert, Palm Springs

35294-3300

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

66160-7357

University of Kansas Medical Center, Kansas City

43210-1240

Arthur G. James Cancer Hospital - Ohio State University, Columbus

19107-5541

Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Kansas Medical Center

OTHER

NCT00005886 - Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer | Biotech Hunter | Biotech Hunter